ATE368116T1 - Schutzantigen des epstein-barr-virus - Google Patents

Schutzantigen des epstein-barr-virus

Info

Publication number
ATE368116T1
ATE368116T1 AT00954003T AT00954003T ATE368116T1 AT E368116 T1 ATE368116 T1 AT E368116T1 AT 00954003 T AT00954003 T AT 00954003T AT 00954003 T AT00954003 T AT 00954003T AT E368116 T1 ATE368116 T1 AT E368116T1
Authority
AT
Austria
Prior art keywords
ebna
barr virus
epstein
protective antigens
vaccine
Prior art date
Application number
AT00954003T
Other languages
English (en)
Inventor
Ralph Steinman
Christian Muenz
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE368116T1 publication Critical patent/ATE368116T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00954003T 1999-08-13 2000-08-10 Schutzantigen des epstein-barr-virus ATE368116T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14897199P 1999-08-13 1999-08-13

Publications (1)

Publication Number Publication Date
ATE368116T1 true ATE368116T1 (de) 2007-08-15

Family

ID=22528253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00954003T ATE368116T1 (de) 1999-08-13 2000-08-10 Schutzantigen des epstein-barr-virus

Country Status (7)

Country Link
EP (1) EP1200594B1 (de)
JP (1) JP2004500335A (de)
AT (1) ATE368116T1 (de)
AU (1) AU775760B2 (de)
CA (1) CA2380991A1 (de)
DE (1) DE60035695T2 (de)
WO (1) WO2001012215A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
WO2003105665A2 (en) * 2002-06-14 2003-12-24 Mayo Foundation For Medical Education And Research Epstein-barr virus-specific immunization
EP1685159B1 (de) 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3-polypeptide
CA2574282A1 (en) 2004-07-21 2006-03-02 Dana-Farber Cancer Institute, Inc. Lentiviral vectors and uses thereof
CA2630218A1 (en) * 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP2827889A1 (de) 2012-03-19 2015-01-28 Deutsches Krebsforschungszentrum B-zell-rezeptorkomplexbindendende proteine mit t-zell-epitopen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0770090A1 (de) * 1994-07-13 1997-05-02 Cornell Research Foundation, Inc. Protein des epstein-barr virus kernantigen 1 und seine expression und anreicherung
CA2180193A1 (en) * 1995-06-28 1996-12-29 Edward Baral Enhancing host immunity against viral infections
EP0871747A1 (de) * 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen

Also Published As

Publication number Publication date
EP1200594A2 (de) 2002-05-02
AU6636200A (en) 2001-03-13
WO2001012215A3 (en) 2001-08-23
DE60035695T2 (de) 2008-04-10
EP1200594B1 (de) 2007-07-25
DE60035695D1 (de) 2007-09-06
AU775760B2 (en) 2004-08-12
JP2004500335A (ja) 2004-01-08
CA2380991A1 (en) 2001-02-22
WO2001012215A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
Long et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines
Khanna et al. Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation
Cohen Vaccine development for Epstein-Barr virus
Münz et al. Immune escape by Epstein–Barr virus associated malignancies
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
Thorley-Lawson et al. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein.
Kallin et al. Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells.
Bourgault et al. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes
Balfour Jr Progress, prospects, and problems in Epstein-Barr virus vaccine development
EP1434596A4 (de) Verwendung von 4-1bb bindenden agenzien zur erhöhung der immunantwort
ES2009350A6 (es) Procedimiento para la preparacion de vectores de expresion que codifican una nueva proteina.
Hislop et al. T-cell responses to EBV
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
MY142842A (en) Vaccine against hpv
EE9800105A (et) Dendriitrakke stimuleeriv faktor
Su et al. The generation of LMP2a‐specific cytotoxic T lymphocytes for the treatment of patients with Epstein‐Barr virus‐positive Hodgkin disease
PT1294893E (pt) Modificacao do antigenio nuclear de hepatite b
Duraiswamy et al. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions
MXPA02002483A (es) Vacuna contra vhb y vph.
DK1523582T3 (da) Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
DE60035695D1 (de) Schutzantigen des epstein-barr-virus
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
Lee Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy
DK0882132T3 (da) Et kombineret humant cytomegalovirus-antigen og anvendelse heraf

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties